Live Breaking News & Updates on European Competence Network

Stay updated with breaking news from European competence network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene. ....

United States , Avapritinib Ayvakit , Prithviraj Bose , Midostaurin Rydapt , International Working Group , American Society Of Hematology Annual Meeting , University Of Texas Md Anderson Cancer Center , International Consensus Classification Of Myeloid Neoplasms , Blueprint Medicines Corp , Touchstone Sm Patient , Iwg Myeloproliferative Neoplasms Research , European Competence Network On Mastocytosis , World Health Organization Classification Of Haematolymphoid Tumours , World Health Organization , Meeting Of The Society Hematologic Oncology , International Consensus Classification , Myeloid Neoplasms , European Competence Network , Annual Meeting , Hematologic Oncology , Cancer Center , Myeloproliferative Neoplasms Research , Cogent Biosciences , Hematology Annual Meeting , Acute Leukemias , World Health Organization Classification ,

Targeted Drug Yields Durable Responses in Rare Blood Neoplasm

email article
Three-quarters of patients with the rare blood disorder advanced systemic mastocytosis responded to treatment with avapritinib (Ayvakit), an interim analysis of a phase II trial found.
Among 32 patients treated with daily avapritinib in the PATHFINDER study, 19% had a complete remission (CR) with partial hematologic recovery, 31% had a partial response, and 25% achieved stable disease, with responses observed in all disease subtypes, reported Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute in Boston.
Avapritinib at a starting dose of 200 mg induced rapid, durable, and improving responses, DeAngelo said during his presentation at the American Association for Cancer Research virtual meeting. Reductions were seen in disease burden based on bone marrow mast cells, reduction in serum tryptase, ....

United States , Dana Farber Cancer Institute , Daniel Deangelo , Ian Ingram , American Association For Cancer Research , International Working Group , European Competence Network On Mastocytosis , Myeloproliferative Neoplasms Research , Eastern Cooperative Oncology Group , American Association , Cancer Research , European Competence Network , Medpage Today , Deputy Managing Editor , ஒன்றுபட்டது மாநிலங்களில் , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , டேனியல் டெங்கேலோ , ஈயந் இஂக்ரம் , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , சர்வதேச வேலை குழு , கிழக்கு கூட்டுறவு புற்றுநோயியல் குழு , அமெரிக்கன் சங்கம் , புற்றுநோய் ஆராய்ச்சி , ஐரோப்பிய திறன் வலைப்பின்னல் , துணை நிர்வகித்தல் ஆசிரியர் ,